The impact of pre-existing cross-reactive immunity on SARS-CoV-2 infection and vaccine responses

The impact of pre-existing cross-reactive immunity on SARS-CoV-2 infection and vaccine responses

Pre-existing cross-reactive immune responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) proteins in infection-naive subjects have been described by several studies. In particular, regions of high homology between SARS-CoV-2 and common cold coronaviruses have been highlighted as...

Полное описание

Библиографические подробности
Главные авторы:	Murray, SM, Ansari, AM, Frater, J, Klenerman, P, Dunachie, S, Barnes, E, Ogbe, A
Формат:	Journal article
Язык:	English
Опубликовано:	Springer Nature 2022

Схожие документы

SARS-CoV-2 antibody responses post-vaccination in UK healthcare workers with pre-existing medical conditions: a cohort study
по: Ward, V, и др.
Опубликовано: (2022)

SARS-CoV-2 antibody responses post-vaccination in UK healthcare workers with pre-existing medical conditions: a cohort study
по: Eleanor Barnes, и др.
Опубликовано: (2022-12-01)

Pre-existing anti-HCoV-OC43 immunity influences the durability and cross-reactivity of humoral response to SARS-CoV-2 vaccination
по: Caiqin Hu, и др.
Опубликовано: (2022-09-01)

IgM responses following SARS-CoV-2 vaccination: insights into protective and pre-existing immunity
по: Judith Fraussen
Опубликовано: (2022-03-01)

Cellular immunity to SARS-CoV-2 following intrafamilial exposure in seronegative family members
по: Cecilia Jay, и др.
Опубликовано: (2023-08-01)

Two doses of SARS-CoV-2 vaccination induce robust immune responses to emerging SARS-CoV-2 variants of concern
по: Skelly, DT, и др.
Опубликовано: (2021)

Vaccine models predict rules for updating vaccines against evolving pathogens such as SARS-CoV-2 and influenza in the context of pre-existing immunity
по: Rajat Desikan, и др.
Опубликовано: (2022-10-01)

Pre-Existing Comorbidities Diminish the Likelihood of Seropositivity after SARS-CoV-2 Vaccination
по: Alok R. Amraotkar, и др.
Опубликовано: (2022-08-01)

Primary ChAdOx1 vaccination does not reactivate pre-existing, cross-reactive immunity
по: Larissa Henze, и др.
Опубликовано: (2023-01-01)

Cellular immunity to SARS-CoV-2 following intrafamilial exposure in seronegative family members
по: Jay, C, и др.
Опубликовано: (2023)

mRNA vaccination drives differential mucosal neutralizing antibody profiles in naïve and SARS-CoV-2 previously-infected individuals
по: Stephanie Longet, и др.
Опубликовано: (2022-09-01)

Booster vaccination against SARS-CoV-2 induces potent immune responses in people with human immunodeficiency virus
по: Fidler, S, и др.
Опубликовано: (2022)

Two doses of SARS-CoV-2 vaccination induce robust immune responses to emerging SARS-CoV-2 variants of concern
по: Donal T. Skelly, и др.
Опубликовано: (2021-08-01)

Pre-existing T cell immunity determines the frequency and magnitude of cellular immune response to two doses of mRNA vaccine against SARS-CoV-2
по: José L. Casado, и др.
Опубликовано: (2022-08-01)

Pre-existing humoral immunity to low pathogenic human coronaviruses exhibits limited cross-reactive antibodies response against SARS-CoV-2 in children
по: Nina Li, и др.
Опубликовано: (2022-10-01)

Pre-Pandemic Cross-Reactive Immunity against SARS-CoV-2 among Siberian Populations
по: Olga N. Shaprova, и др.
Опубликовано: (2023-12-01)

Aging and CMV Infection Affect Pre-existing SARS-CoV-2-Reactive CD8+ T Cells in Unexposed Individuals
по: Norihide Jo, и др.
Опубликовано: (2021-08-01)

SARS-CoV-2 spike-reactive naïve B cells and pre-existing memory B cells contribute to antibody responses in unexposed individuals after vaccination
по: Shishan Teng, и др.
Опубликовано: (2024-02-01)

Potential Cross-Reactive Immunity to SARS-CoV-2 From Common Human Pathogens and Vaccines
по: Pedro A. Reche
Опубликовано: (2020-10-01)

SARS-CoV-2-specific immune responses and clinical outcomes after COVID-19 vaccination in patients with immune-suppressive disease
по: Barnes, E, и др.
Опубликовано: (2023)

SARS-CoV-2 and Pre-existing Vascular Diseases: Guilt by Association?
по: Grigorios Voulalas, и др.
Опубликовано: (2021-05-01)

The mRNA-1273 Vaccine Induces Cross-Variant Antibody Responses to SARS-CoV-2 With Distinct Profiles in Individuals With or Without Pre-Existing Immunity
по: Sonia Tejedor Vaquero, и др.
Опубликовано: (2021-09-01)

Frequent Infection of Cats With SARS-CoV-2 Irrespective of Pre-Existing Enzootic Coronavirus Immunity, Brazil 2020
по: Edmilson F. de Oliveira-Filho, и др.
Опубликовано: (2022-04-01)

Immune Response to SARS-CoV-2 Vaccines
по: Navya Bellamkonda, и др.
Опубликовано: (2022-06-01)

Pre-existing cross-reactive neutralizing activity against SARS-CoV-2 and seasonal coronaviruses prior to the COVID-19 pandemic (2014-2019) with limited immunity against recent emerging SARS-CoV-2 variants, Vietnam
по: Thi Thanh Ngan Nguyen, и др.
Опубликовано: (2024-02-01)

Cross-reactive immunity to SARS-CoV-2 and related coronaviruses
по: Jay, C
Опубликовано: (2023)

Age- and sex-specific differences in immune responses to BNT162b2 COVID-19 and live-attenuated influenza vaccines in UK adolescents
по: Cecilia Jay, и др.
Опубликовано: (2023-10-01)

Challenges in Dengue Vaccines Development: Pre-existing Infections and Cross-Reactivity
по: Abdullah M. Izmirly, и др.
Опубликовано: (2020-06-01)

Poor antibody responses to SARS-CoV-2 infection or vaccination are associated with high re-infection rates in haemodialysis and renal transplant patients
по: Shankar, S, и др.
Опубликовано: (2021)

Pre-Pandemic Cross-Reactive Immunity against SARS-CoV-2 among Central and West African Populations
по: Marc Souris, и др.
Опубликовано: (2022-10-01)

Pre-Existing Microbiome Signature in a SARS-CoV-2 Discordant Family
по: Sabine Hazan
Опубликовано: (2022-02-01)

SARS-CoV-2 in pre-existing autoimmune myasthenia gravis: An institutional experience
по: Nitisha Goyal, и др.
Опубликовано: (2021-03-01)

Large clones of pre-existing T cells drive early immunity against SARS-COV-2 and LCMV infection
по: Martina Milighetti, и др.
Опубликовано: (2023-06-01)

Superior humoral immunity in vaccinated SARS-CoV-2 convalescence as compared to SARS-COV-2 infection or vaccination
по: Krystallenia Paniskaki, и др.
Опубликовано: (2022-10-01)

Reactivation of Varicella Zoster Virus after Vaccination for SARS-CoV-2
по: Mina Psichogiou, и др.
Опубликовано: (2021-06-01)

Cross-reactive antibodies after SARS-CoV-2 infection and vaccination
по: Marloes Grobben, и др.
Опубликовано: (2021-11-01)

Vaccine‐breakthrough infection by the SARS‐CoV‐2 omicron variant elicits broadly cross‐reactive immune responses
по: Runhong Zhou, и др.
Опубликовано: (2022-01-01)

Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV
по: Xiuyuan Ou, и др.
Опубликовано: (2020-03-01)

SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway
по: Willett, BJ, и др.
Опубликовано: (2022)

The impact of cross-reactive immunity on the emergence of SARS-CoV-2 variants
по: Thompson, RN, и др.
Опубликовано: (2023)